Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come
Chunsong Hu(Nanchang University), Tengiz Tkebuchava(Boston University), Qinghua Wu(Ministry of Education of the People's Republic of China), Dayi Hu(Beihang University)
Cited by 16
Related Papers
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
|New England Journal of Medicine|2013|603
VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema
|Journal of Clinical Investigation|2003|262
Stroke prevention in atrial fibrillation—An Asian stroke perspective
|Heart Rhythm|2013|153
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
|Journal of Thrombosis and Thrombolysis|2011|120
D‐dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial
|Journal of Thrombosis and Haemostasis|2014|115